Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BI 1358894 with Itraconazole
NCT03843151Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bi 1358894 in major depressive disorder (MDD), post-traumatic stress disorder (PTSD) and borderline personality disorder (BPD), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1358894 in Plasma Over the Time Interval From 0 Extrapolated to Infinity and Maximum Measured Concentration of BI 1358894 in Plasma. Started Mar 2019; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT03843151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843151.